Momenta Pharmaceuticals Inc (NASDAQ:MNTA) (TREND ANALYSIS) shares were traded with no significant volume change. The stock closed last trading session at $21.5, up by 0.56%, with a volume of 1,354,404 shares against an average volume for the last 3 months of 1,099,950.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
Momenta Pharmaceuticals Inc (NASDAQ:MNTA) stock is currently trading 2.89% below its 52-week-high, 129.21% above its 52-week-low. The 1-year stock price history is in the range of $9.38 – $22.14. Momenta Pharmaceuticals Inc (MNTA) has a price to book ratio of 5.55 versus Healthcare sector average of 26.53. MNTA stock price has outperformed the Nasdaq by 72.5%. The Biotechnology company is currently valued at $1.21 billion and its share price closed the last trading session at $21.5. The stock has a 50-day moving average of $19.46 and a 200-day moving average of $14.59.
Momenta Pharmaceuticals Inc (MNTA) current short interest stands at 8.67 million shares. It has increased by 9% from the same period of last month. Around 18% of the company’s shares, which are float, are short sold. With a 10-days average volume of 1.35 million shares, the number of days required to cover the short positions stand at 6.5 days.
MNTA reported last quarter earnings on May 01. The Biotechnology company announced earnings per share of $-0.4 against a consensus Street estimate of $-0.48, beating the average estimate by $0.08. This corresponds to a decrease of $0.03 compared to the same quarter of the previous fiscal year.
Is this a Buying Opportunity? Click here for a free Trend Analysis Report
There are currently nine analysts that cover Momenta Pharmaceuticals Inc stock. Of those nine, five have a Buy rating, three have a Hold rating and one has a Sell rating. On a consensus basis this yields to an Overweight rating. The consensus target price stands at $20.11.
A recent analyst activity consisted of Leerink Swann reiterating their Outperform stance on May 4. Leerink Swann increased their price target on MNTA from $24 to $25. This corresponds to a 16.28% upside from the last closing price. On the date of report, the stock closed at $19.07.
Maxim Group downgraded their Buy rating to Sell on January 23. On the date of report, the stock closed at $10.63.
Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company specializes in sequencing and engineering of complex sugars for the development of improved versions of existing drugs, the development of novel drugs, and the discovery of new biological processes. Momenta also develops technology-enabled generic products.